Detection of disease-associated α-synuclein in the cerebrospinal fluid: A feasibility study

Clinical Neuropathology

Volumn 33, Issue 5, 2014, Pages 329-334

  Unterberger, Ursula ^a   Lachmann, Ingolf ^b   Voigtländer, Till ^a   Pirker, Walter ^c   Berghoff, Anna S ^a,c   Flach, Katharina ^b   Wagner, Uta ^b   Geneste, Aline ^d   Perret Liaudet, Armand ^d,e   Kovacs, Gabor G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Roboscreen GmbH Leipzig   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITÉ DE LYON   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

Beadassay; Cerebrospinal fluid; Dementia with Lewy bodies; Parkinson's disease dementia; Synucleinopathy; synuclein

Indexed keywords

ALPHA SYNUCLEIN; PROTEIN 14 3 3; DISEASE ASSOCIATED ALPHA SYNUCLEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FALSE NEGATIVE RESULT; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUMBAR PUNCTURE; MALE; MIDDLE AGED; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RELIABILITY; VERY ELDERLY; BETA SHEET; CONTROLLED CLINICAL TRIAL; DEMENTIA; ELISA KIT; MOLECULAR WEIGHT; PARKINSON DISEASE DEMENTIA; TIME OF DEATH;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS;

EID: 84906056706     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300796     Document Type: Article

References (20)

1. Kovacs GG, Botond G, Budka H. Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol. 2010; 119: 389-408. CrossRef PubMed
2. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, et al Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65: 1863-1872. Cross-Ref PubMed
3. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001; 2: 492-501. CrossRef PubMed
4. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011; 10: 230-240. CrossRef PubMed
5. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun. 2006; 349: 162-166. CrossRef PubMed
6. Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, El-Agnaf OM, Yamada M. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 2009; 1251: 1-6. CrossRef PubMed
7. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord. 2011; 26: 1428-1435. CrossRef PubMed
8. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta Neuropathol. 2013; 126: 683-697. CrossRef PubMed
9. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE. 2013; 8: e53250. Cross-Ref PubMed
10. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord. 2012; 26: 213-216. CrossRef PubMed
11. Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis. 2010; 22: 87-95. PubMed
12. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008; 213: 315-325. Cross-Ref PubMed
13. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol. 2013; 9: 131-140. CrossRef PubMed
14. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alphasynuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006; 20: 419-425. CrossRef PubMed
15. Kovacs GG, Breydo L, Green R, Kis V, Puska G, Lo{double acute}rincz P, Perju-Dumbrava L, Giera R, Pirker W, Lutz M, Lachmann I, Budka H, Uversky VN, Molnár K, László L. Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol Dis. 2014; 69C: 76-92. CrossRef PubMed
16. Kovacs GG, Wagner U, Dumont B, Pikkarainen M, Osman AA, Streichenberger N, Leisser I, Verchère J, Baron T, Alafuzoff I, Budka H, Perret-Liaudet A, Lachmann I. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012; 124: 37-50. CrossRef PubMed
17. Emre M. Treatment of dementia associated with Parkinson's disease. Parkinsonism Relat Disord. 2007; 13 (Suppl 3): S457-S461. CrossRef PubMed
18. Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol. 2010; 29: 271-288. CrossRef PubMed
19. Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. PLoS ONE. 2013; 8: e67898.CrossRef PubMed
20. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010; 75: 1766-1772. CrossRef PubMed